<code id='477A789789'></code><style id='477A789789'></style>
    • <acronym id='477A789789'></acronym>
      <center id='477A789789'><center id='477A789789'><tfoot id='477A789789'></tfoot></center><abbr id='477A789789'><dir id='477A789789'><tfoot id='477A789789'></tfoot><noframes id='477A789789'>

    • <optgroup id='477A789789'><strike id='477A789789'><sup id='477A789789'></sup></strike><code id='477A789789'></code></optgroup>
        1. <b id='477A789789'><label id='477A789789'><select id='477A789789'><dt id='477A789789'><span id='477A789789'></span></dt></select></label></b><u id='477A789789'></u>
          <i id='477A789789'><strike id='477A789789'><tt id='477A789789'><pre id='477A789789'></pre></tt></strike></i>

          focus

          focus

          author:fashion    Page View:5
          Boston Scientific headquarters -- Health coverage from STAT
          Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

          Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

          It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

          advertisement

          Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          United colonoscopy coverage change 'may cost lives,' doctors say
          United colonoscopy coverage change 'may cost lives,' doctors say

          AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

          read more
          Report: NIH
          Report: NIH

          MarkWilson/NewsmakersWASHINGTON—ClinicaltrialsthattheNationalInstitutesofHealthfundsoftenenrollfewer

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          Adam's Biotech Scorecard: Do Sarepta's exon

          ThisistheonlineeditionofAdam’sBiotechScorecard,asubscriber-onlynewsletter.STAT+subscriberscansignuph